Literature DB >> 34904152

Immunological Regulation of Intestinal Fibrosis in Inflammatory Bowel Disease.

Giorgos Bamias1, Theresa T Pizarro2,3, Fabio Cominelli2,3.   

Abstract

Intestinal fibrosis is a late-stage phenotype of inflammatory bowel disease (IBD), which underlies most of the long-term complications and surgical interventions in patients, particularly those with Crohn's disease. Despite these issues, antifibrotic therapies are still scarce, mainly due to the current lack of understanding concerning the pathogenetic mechanisms that mediate fibrogenesis in patients with chronic intestinal inflammation. In the current review, we summarize recent evidence regarding the cellular and molecular factors of innate and adaptive immunity that are considered critical for the initiation and amplification of extracellular matrix deposition and stricture formation. We focus on the role of cytokines by dissecting the pro- vs antifibrotic components of the immune response, while taking into consideration their temporal association to the progressive stages of the natural history of IBD. We critically present evidence from animal models of intestinal fibrosis and analyze inflammation-fibrosis interactions that occur under such experimental scenarios. In addition, we comment on recent findings from large-scale, single-cell profiling of fibrosis-relevant populations in IBD patients. Based on such evidence, we propose future potential targets for antifibrotic therapies to treat patients with IBD.
© 2021 Crohn’s & Colitis Foundation. Published by Oxford University Press. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  Crohn’s disease; cytokines; fibrosis; immunoregulation; myofibroblasts; ulcerative colitis

Mesh:

Year:  2022        PMID: 34904152      PMCID: PMC8919810          DOI: 10.1093/ibd/izab251

Source DB:  PubMed          Journal:  Inflamm Bowel Dis        ISSN: 1078-0998            Impact factor:   7.290


  125 in total

1.  Rates and trends for inpatient surgeries in pediatric Crohn's disease in the United States from 2003 to 2012.

Authors:  Audrey L Stokes; Afif N Kulaylat; Dorothy V Rocourt; Christopher S Hollenbeak; Walter Koltun; Tolulope Falaiye
Journal:  J Pediatr Surg       Date:  2017-12-05       Impact factor: 2.545

2.  Subgroup analysis of the placebo-controlled CHARM trial: increased remission rates through 3 years for adalimumab-treated patients with early Crohn's disease.

Authors:  S Schreiber; W Reinisch; J F Colombel; W J Sandborn; D W Hommes; A M Robinson; B Huang; K G Lomax; P F Pollack
Journal:  J Crohns Colitis       Date:  2012-06-16       Impact factor: 9.071

3.  Role of Interleukin-17 in Pathogenesis of Intestinal Fibrosis in Mice.

Authors:  Jian Li; Lan Liu; Qiu Zhao; Min Chen
Journal:  Dig Dis Sci       Date:  2019-12-05       Impact factor: 3.199

Review 4.  TNBS-colitis.

Authors:  M Neurath; I Fuss; W Strober
Journal:  Int Rev Immunol       Date:  2000       Impact factor: 5.311

Review 5.  Host responses in tissue repair and fibrosis.

Authors:  Jeremy S Duffield; Mark Lupher; Victor J Thannickal; Thomas A Wynn
Journal:  Annu Rev Pathol       Date:  2012-10-22       Impact factor: 23.472

Review 6.  Intestinal fibrosis in IBD--a dynamic, multifactorial process.

Authors:  Florian Rieder; Claudio Fiocchi
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2009-04       Impact factor: 46.802

7.  IL-13 signaling via IL-13R alpha2 induces major downstream fibrogenic factors mediating fibrosis in chronic TNBS colitis.

Authors:  Stefan Fichtner-Feigl; Cheryl A Young; Atsushi Kitani; Edward K Geissler; Hans-Jürgen Schlitt; Warren Strober
Journal:  Gastroenterology       Date:  2008-09-11       Impact factor: 22.682

8.  Involvement of interleukin-17A-induced expression of heat shock protein 47 in intestinal fibrosis in Crohn's disease.

Authors:  Yusuke Honzawa; Hiroshi Nakase; Masahiro Shiokawa; Takuya Yoshino; Hirotsugu Imaeda; Minoru Matsuura; Yuzo Kodama; Hiroki Ikeuchi; Akira Andoh; Yoshiharu Sakai; Kazuhiro Nagata; Tsutomu Chiba
Journal:  Gut       Date:  2014-02-17       Impact factor: 23.059

9.  The role of interleukin 17 in Crohn's disease-associated intestinal fibrosis.

Authors:  Paolo Biancheri; Sylvia Lf Pender; Francesca Ammoscato; Paolo Giuffrida; Gianluca Sampietro; Sandro Ardizzone; Amir Ghanbari; Renata Curciarello; Alessandra Pasini; Giovanni Monteleone; Gino R Corazza; Thomas T Macdonald; Antonio Di Sabatino
Journal:  Fibrogenesis Tissue Repair       Date:  2013-07-08

Review 10.  ECM remodelling in IBD: innocent bystander or partner in crime? The emerging role of extracellular molecular events in sustaining intestinal inflammation.

Authors:  Elee Shimshoni; Doron Yablecovitch; Liran Baram; Iris Dotan; Irit Sagi
Journal:  Gut       Date:  2014-11-21       Impact factor: 23.059

View more
  2 in total

Review 1.  Intestinal strictures in Crohn's disease: a 2021 update.

Authors:  Xiaoxuan Lin; Yu Wang; Zishan Liu; Sinan Lin; Jinyu Tan; Jinshen He; Fan Hu; Xiaomin Wu; Subrata Ghosh; Minhu Chen; Fen Liu; Ren Mao
Journal:  Therap Adv Gastroenterol       Date:  2022-06-21       Impact factor: 4.802

Review 2.  Investigating the possible mechanisms of pirfenidone to be targeted as a promising anti-inflammatory, anti-fibrotic, anti-oxidant, anti-apoptotic, anti-tumor, and/or anti-SARS-CoV-2.

Authors:  Samar A Antar; Mohamed A Saleh; Ahmed A Al-Karmalawy
Journal:  Life Sci       Date:  2022-10-07       Impact factor: 6.780

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.